JP2022549172A5 - - Google Patents
Info
- Publication number
- JP2022549172A5 JP2022549172A5 JP2022517452A JP2022517452A JP2022549172A5 JP 2022549172 A5 JP2022549172 A5 JP 2022549172A5 JP 2022517452 A JP2022517452 A JP 2022517452A JP 2022517452 A JP2022517452 A JP 2022517452A JP 2022549172 A5 JP2022549172 A5 JP 2022549172A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antibody
- acid sequence
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025112231A JP2025165930A (ja) | 2019-09-18 | 2025-07-02 | Gipr抗体及びglp-1とのその融合タンパク質、並びにその医薬組成物及び用途 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910882351.2 | 2019-09-18 | ||
| CN201910882351.2A CN112521501A (zh) | 2019-09-18 | 2019-09-18 | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
| PCT/CN2020/115483 WO2021052349A1 (zh) | 2019-09-18 | 2020-09-16 | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025112231A Division JP2025165930A (ja) | 2019-09-18 | 2025-07-02 | Gipr抗体及びglp-1とのその融合タンパク質、並びにその医薬組成物及び用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022549172A JP2022549172A (ja) | 2022-11-24 |
| JP2022549172A5 true JP2022549172A5 (cg-RX-API-DMAC7.html) | 2023-09-27 |
Family
ID=74883118
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517452A Pending JP2022549172A (ja) | 2019-09-18 | 2020-09-16 | Gipr抗体及びglp-1とのその融合タンパク質、並びにその医薬組成物及び用途 |
| JP2025112231A Pending JP2025165930A (ja) | 2019-09-18 | 2025-07-02 | Gipr抗体及びglp-1とのその融合タンパク質、並びにその医薬組成物及び用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025112231A Pending JP2025165930A (ja) | 2019-09-18 | 2025-07-02 | Gipr抗体及びglp-1とのその融合タンパク質、並びにその医薬組成物及び用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220411520A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4063385A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022549172A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220063221A (cg-RX-API-DMAC7.html) |
| CN (4) | CN112521501A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020350715B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3154756A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022003251A (cg-RX-API-DMAC7.html) |
| TW (2) | TWI889705B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021052349A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4352104A4 (en) * | 2021-06-09 | 2025-06-04 | Swiftnovo Therapeutics Inc. | Therapeutics and methods for treating or ameliorating metabolic disorders |
| AU2023337288A1 (en) * | 2022-09-08 | 2025-03-13 | Gmax Biopharm Llc | Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof |
| US20260139314A1 (en) * | 2022-10-12 | 2026-05-21 | Seoul National University Hospital | Composition and method for predicting sulfonylurea dependency using gipr marker |
| CN117986361A (zh) * | 2022-11-02 | 2024-05-07 | 苏州康宁杰瑞生物科技有限公司 | 一种gipr结合蛋白及其应用 |
| CN122094712A (zh) * | 2023-10-31 | 2026-05-26 | 山东博安生物技术股份有限公司 | Gipr阻断型抗体及其抗体偶联物 |
| TW202611076A (zh) * | 2024-05-15 | 2026-03-16 | 大陸商信立泰(成都)生物技術有限公司 | 一種抗gipr抗體或其抗原結合片段及用途 |
| WO2025252023A1 (en) * | 2024-06-03 | 2025-12-11 | Fortvita Biologics Inc. | Modulators for gipr, glp1r and/or gcgr and uses thereof |
| WO2026021575A1 (zh) * | 2024-07-26 | 2026-01-29 | 鸿运华宁(杭州)生物医药有限公司 | 一种gipr抗体融合蛋白质的药用稳定溶液制剂及其应用 |
| WO2026056998A1 (zh) * | 2024-09-12 | 2026-03-19 | 江苏恒瑞医药股份有限公司 | Gipr结合分子及医药用途 |
| WO2026093993A1 (en) * | 2024-11-01 | 2026-05-07 | Janssen Biotech, Inc. | Methods and systems for enhanced multispecific metabolic and cellular targeting |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| PT672141E (pt) | 1992-10-23 | 2003-09-30 | Immunex Corp | Metodos de preparacao de proteinas oligomericas soluveis |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| SE9802080D0 (sv) | 1998-06-11 | 1998-06-11 | Hellstroem | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
| AU5027299A (en) | 1998-07-31 | 2000-02-28 | Novo Nordisk A/S | Use of glp-1 and analogues for preventing type ii diabetes |
| US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
| MY155270A (en) | 1998-09-24 | 2015-09-30 | Lilly Co Eli | Use of glp-1 or analogs in treatment of stroke |
| GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
| GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
| CN104080767A (zh) * | 2011-12-12 | 2014-10-01 | 瑞塞普托斯公司 | 新的glp-1受体调节剂 |
| CN104371019B (zh) * | 2013-08-13 | 2019-09-10 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| CN117106085A (zh) * | 2015-12-23 | 2023-11-24 | 美国安进公司 | 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法 |
| EP4480537A3 (en) * | 2017-01-17 | 2025-03-12 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
| CA3062194A1 (en) * | 2017-06-20 | 2018-12-27 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
| JP7250706B2 (ja) * | 2017-06-21 | 2023-04-03 | アムジエン・インコーポレーテツド | 胃抑制ペプチド受容体(gipr)に対するアンタゴニスト結合タンパク質/glp-1受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法 |
| CN117126279A (zh) * | 2018-03-20 | 2023-11-28 | 鸿运华宁(杭州)生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
-
2019
- 2019-09-18 CN CN201910882351.2A patent/CN112521501A/zh active Pending
-
2020
- 2020-09-16 WO PCT/CN2020/115483 patent/WO2021052349A1/zh not_active Ceased
- 2020-09-16 CN CN202310832321.7A patent/CN116942811A/zh active Pending
- 2020-09-16 MX MX2022003251A patent/MX2022003251A/es unknown
- 2020-09-16 KR KR1020227012130A patent/KR20220063221A/ko active Pending
- 2020-09-16 AU AU2020350715A patent/AU2020350715B2/en active Active
- 2020-09-16 CN CN202510478075.9A patent/CN120289653A/zh active Pending
- 2020-09-16 CA CA3154756A patent/CA3154756A1/en active Pending
- 2020-09-16 US US17/761,128 patent/US20220411520A1/en active Pending
- 2020-09-16 EP EP20866016.7A patent/EP4063385A4/en active Pending
- 2020-09-16 CN CN202080065099.7A patent/CN114641495B/zh active Active
- 2020-09-16 JP JP2022517452A patent/JP2022549172A/ja active Pending
- 2020-09-17 TW TW109132123A patent/TWI889705B/zh active
- 2020-09-17 TW TW114122821A patent/TW202613177A/zh unknown
-
2025
- 2025-07-02 JP JP2025112231A patent/JP2025165930A/ja active Pending